Forte Biosciences (FBRX) Non-Current Debt (2016 - 2019)

Forte Biosciences (FBRX) has reported Non-Current Debt for 4 consecutive years, with $22.1 million the latest figure, recorded in Q2 2019.

• In Q2 2019, Non-Current Debt fell 14.8% year-over-year to $22.1 million; the TTM figure through Jun 2019 stood at $22.1 million (down 14.8% YoY), while the FY2018 annual figure was $26.2 million, up 622.79% from the prior year.
• Non-Current Debt fell to $22.1 million in Q2 2019 per FBRX's latest filing, from $24.1 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $26.2 million in Q4 2018 and bottomed at $2.0 million in Q1 2018.
• Historically, Non-Current Debt has averaged $14.6 million across 4 years, with a median of $10.2 million in 2016.
• Annual changes were most pronounced in 2018 — Non-Current Debt slumped 77.02% — and 2019, when it surged 1124.09%.
• Forte Biosciences' Non-Current Debt stood at $10.2 million in 2016, then sank by 64.6% to $3.6 million in 2017, then jumped by 622.79% to $26.2 million in 2018, then fell by 15.73% to $22.1 million in 2019.
• Business Quant data shows FBRX's Non-Current Debt at $22.1 million in Q2 2019, $24.1 million in Q1 2019, and $26.2 million in Q4 2018.